CN1043647C - 新的肽化合物 - Google Patents

新的肽化合物 Download PDF

Info

Publication number
CN1043647C
CN1043647C CN92103241A CN92103241A CN1043647C CN 1043647 C CN1043647 C CN 1043647C CN 92103241 A CN92103241 A CN 92103241A CN 92103241 A CN92103241 A CN 92103241A CN 1043647 C CN1043647 C CN 1043647C
Authority
CN
China
Prior art keywords
group
compound
salt
alkyl
target compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN92103241A
Other languages
English (en)
Chinese (zh)
Other versions
CN1066660A (zh
Inventor
高杉寿
田中明人
酒井裕义
石川贵敏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujisawa Pharmaceutical Co Ltd
Original Assignee
Fujisawa Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB919110298A external-priority patent/GB9110298D0/en
Priority claimed from GB929202260A external-priority patent/GB9202260D0/en
Application filed by Fujisawa Pharmaceutical Co Ltd filed Critical Fujisawa Pharmaceutical Co Ltd
Publication of CN1066660A publication Critical patent/CN1066660A/zh
Application granted granted Critical
Publication of CN1043647C publication Critical patent/CN1043647C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06104—Dipeptides with the first amino acid being acidic
    • C07K5/06113—Asp- or Asn-amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/75—Fibrinogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06104—Dipeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN92103241A 1991-05-13 1992-05-12 新的肽化合物 Expired - Fee Related CN1043647C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB919110298A GB9110298D0 (en) 1991-05-13 1991-05-13 New peptide compound and a process for the preparation thereof
GB9110298.8 1991-05-13
GB9202260.7 1992-02-03
GB929202260A GB9202260D0 (en) 1992-02-03 1992-02-03 New peptide compound and a process for the preparation thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN95109813A Division CN1120047A (zh) 1991-05-13 1995-08-18 新的肽化合物及其制备方法

Publications (2)

Publication Number Publication Date
CN1066660A CN1066660A (zh) 1992-12-02
CN1043647C true CN1043647C (zh) 1999-06-16

Family

ID=26298895

Family Applications (2)

Application Number Title Priority Date Filing Date
CN92103241A Expired - Fee Related CN1043647C (zh) 1991-05-13 1992-05-12 新的肽化合物
CN95109813A Pending CN1120047A (zh) 1991-05-13 1995-08-18 新的肽化合物及其制备方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN95109813A Pending CN1120047A (zh) 1991-05-13 1995-08-18 新的肽化合物及其制备方法

Country Status (15)

Country Link
US (1) US5574016A (enExample)
EP (1) EP0513675B1 (enExample)
JP (1) JP2606528B2 (enExample)
KR (1) KR920021579A (enExample)
CN (2) CN1043647C (enExample)
AT (1) ATE142641T1 (enExample)
AU (1) AU662522B2 (enExample)
CA (1) CA2068478A1 (enExample)
DE (1) DE69213546T2 (enExample)
DK (1) DK0513675T3 (enExample)
ES (1) ES2091359T3 (enExample)
GR (1) GR3021182T3 (enExample)
HU (2) HUT61780A (enExample)
IL (1) IL101839A (enExample)
TW (1) TW203057B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5272162A (en) * 1992-07-02 1993-12-21 G. D. Searle & Co. Platelet aggregation inhibitors
US5354738A (en) * 1992-09-04 1994-10-11 G. D. Searle & Co. Platelet aggregation inhibitors
US5314902A (en) * 1993-01-27 1994-05-24 Monsanto Company Urea derivatives useful as platelet aggregation inhibitors
DE4309867A1 (de) * 1993-03-26 1994-09-29 Cassella Ag Neue Harnstoffderivate, ihre Herstellung und Verwendung
EP0690847A1 (en) * 1993-03-29 1996-01-10 Zeneca Limited Heterocyclic compounds as platelet aggregation inhibitors
US5652242A (en) * 1993-03-29 1997-07-29 Zeneca Limited Heterocyclic derivatives
US5750754A (en) * 1993-03-29 1998-05-12 Zeneca Limited Heterocyclic compounds
ES2159798T3 (es) * 1993-03-29 2001-10-16 Astrazeneca Ab Derivados heterociclicos como inhibidores de la agregacion plaquetaria.
US5753659A (en) * 1993-03-29 1998-05-19 Zeneca Limited Heterocyclic compouds
US5463011A (en) * 1993-06-28 1995-10-31 Zeneca Limited Acid derivatives
GB9313285D0 (en) * 1993-06-28 1993-08-11 Zeneca Ltd Acid derivatives
GB9313268D0 (en) * 1993-06-28 1993-08-11 Zeneca Ltd Chemical compounds
US5780590A (en) * 1993-10-15 1998-07-14 Rhone-Poulenc Rorer Pharmaceuticals Inc. Antithrombotic azacycloalkylalkanoyl peptides and pseudopeptides
JPH09505290A (ja) * 1993-11-19 1997-05-27 ジー．ディー．サール アンド カンパニー Ｎ‐［Ｎ‐［５‐［４‐（アミノイミノメチル）フェニル］‐１‐オキソペンチル］‐Ｌ‐α‐アスパルチル］‐Ｌ‐フェニルアラニンまたはそのエステル並びにそれらの医薬的に許容される塩類の経皮的組成物
US6387880B1 (en) 1994-10-24 2002-05-14 G.D. Searle & Co. Transdermal N-[N-[5-[4-(aminoiminomethly)phenyl]-1-oxopentyl]-L-α-aspartyl]-L-phenylalainine or its esters and their pharmaceutically acceptable salts
EP0790247A4 (en) * 1994-11-01 2000-07-19 Terumo Corp TETRAHYDROISOCHINOLINE DERIVATIVES AND MEDICINAL PRODUCTS CONTAINING THEM
US5766932A (en) * 1995-12-20 1998-06-16 Hoechst Marion Roussel, Inc. Process for preparing N-acetyl(L)-4-cyanophenylalanine from a mixture of the corresponding D,L ethyl esters using subtilisin
CN1087349C (zh) * 1995-12-20 2002-07-10 阿温蒂斯药物公司 N－乙酰基－(L)－4－氰基苯丙氨酸Ac-(L)-Phe(4－CN)－OH与N－乙酰基－(L)－对脒基苯丙氨酸－环己基甘氨酸－β－（3－N－甲基吡啶鎓）－丙氨酸AC－（L）－PAPh－chg－PaIMe(3)-NH2的新颖的制备方法
JP2001131078A (ja) * 1999-11-09 2001-05-15 Iatron Lab Inc 新規活性固定化血小板及びその製造方法
DE10005631A1 (de) 2000-02-09 2001-08-23 Max Planck Gesellschaft Arginin-Mimetika als Faktor X¶a¶-Inhibitoren
CA2421575C (en) * 2000-09-06 2011-07-12 Emisphere Technologies, Inc. Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4857508A (en) * 1987-12-03 1989-08-15 Monsanto Company Novel platelet-aggregation inhibitor peptide derivatives
US5039805A (en) * 1988-12-08 1991-08-13 Hoffmann-La Roche Inc. Novel benzoic and phenylacetic acid derivatives
CA2008116C (en) * 1989-02-23 2001-11-20 Thomas Weller Glycine derivatives
CA2037153A1 (en) * 1990-03-09 1991-09-10 Leo Alig Acetic acid derivatives
AU646838B2 (en) * 1990-03-09 1994-03-10 F. Hoffmann-La Roche Ag Acetic acid derivatives
AU662142B2 (en) * 1991-03-06 1995-08-24 G.D. Searle & Co. Phenyl amidines derivatives useful as platelet aggregation inhibitors
DE4212304A1 (de) * 1992-04-13 1993-10-14 Cassella Ag Asparaginsäurederivate, ihre Herstellung und Verwendung

Also Published As

Publication number Publication date
TW203057B (enExample) 1993-04-01
US5574016A (en) 1996-11-12
CA2068478A1 (en) 1992-11-14
DE69213546D1 (de) 1996-10-17
IL101839A (en) 1996-12-05
ES2091359T3 (es) 1996-11-01
CN1066660A (zh) 1992-12-02
HU9201578D0 (en) 1992-08-28
HUT61780A (en) 1993-03-01
DE69213546T2 (de) 1997-02-27
GR3021182T3 (en) 1996-12-31
DK0513675T3 (da) 1996-09-30
EP0513675B1 (en) 1996-09-11
IL101839A0 (en) 1992-12-30
HU211266A9 (en) 1995-11-28
ATE142641T1 (de) 1996-09-15
AU662522B2 (en) 1995-09-07
JPH05148207A (ja) 1993-06-15
KR920021579A (ko) 1992-12-18
AU1614492A (en) 1992-11-19
CN1120047A (zh) 1996-04-10
EP0513675A1 (en) 1992-11-19
JP2606528B2 (ja) 1997-05-07

Similar Documents

Publication Publication Date Title
CN1043647C (zh) 新的肽化合物
CN1203089C (zh) 新化合物
CN1040541C (zh) 新型多肽化合物的制备方法
CN1149210C (zh) 凝血酶抑制剂
CN1034869C (zh) 肽类化合物及其可药用盐的制备方法
CN1022187C (zh) 三环化合物的制备方法
CN1041941A (zh) 苯并二氮杂衍生物的制备方法
CN1505617A (zh) 作为Met-AP2抑制剂的肽
CN1067883A (zh) 纤维蛋白原受体拮抗剂
CN1214011C (zh) 作为整联蛋白拮抗剂的间－氮杂环氨基苯甲酸化合物及其衍生物
CN1016778B (zh) 螺-取代的戊二酸单酰胺
CN101077875A (zh) 硼酸酯和硼酸化合物,其合成和应用
CN1174504A (zh) 促进生长激素释放的哌啶、吡咯烷和六氢－1h－吖庚因
CN1192729A (zh) 苯甲酰胺衍生物和它们作为后叶加压素拮抗剂的应用
CN1037156A (zh) 肽类化合物、其制备方法及含有这类化合物的药物组合物
CN1211991A (zh) 具有生长激素释放性质的化合物
CN87101164A (zh) 次膦酸衍生物
CN1356995A (zh) 取代的苯并咪唑
CN1066150C (zh) 作为基质金属蛋白酶抑制剂的桥式吲哚
CN1076345C (zh) 2,3－二氨基丙酸衍生物
CN1041919C (zh) 用作血小板激活因子拮抗物的N-(3-哌啶基碳酰)-β-氨基丙酸衍生物
CN1169986A (zh) 2,9－二氨基和2－氨基－8－氨基甲酰基－4－羟基－链烷酸酰胺衍生物
CN1491942A (zh) N-[n-n-(4-（哌啶-4-基)丁酰基)-n-乙基甘氨酰基]化合物的不吸湿的稳定结晶形式
CN1097192A (zh) 逆转录酶病毒蛋白酶抑制剂
CN1204889C (zh) 粘附受体拮抗剂

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee